When should prophylaxis therapy in inhibitor patients be considered

摘要: Currently, patients with severe haemophilia can expect to lead a relatively normal life including prevention of disabling arthropathy as result the development factor replacement therapy and advances in understanding use such given prophylactically. Unfortunately, subset develops neutralizing antibodies termed inhibitors rendering ineffective. These frequently develop recurrent joint bleeding resulting arthropathy. Until recently, prophylactic was not considered for because perceived lack an effective therapeutic agent. However, accumulation case reports recent prospective study have suggested that prophylaxis currently available bypassing agents could be appears safe selected cases. This report will review current data on suggest specific situations which inhibitor considered.